Testicular Cancer


Why testicular cancer?

In most cases (better than 95%) a diagnosis of testicular cancer means established treatments and a good outcome. Unfortunately, there are a small proportion of men and boys who do not face that good outcome, and more needs to be done to support these men through diagnosis and treatment and into a long and healthy life after cancer.


How we're tackling testicular cancer

We bring people together to collaborate on solutions that will fundamentally change the way men with testicular cancer are treated and supported. We're funding initiatives that:

1. Deepen the worldwide scientific understanding of testicular cancer and its treatments and outcomes.


2. Provide proactive support to men and boys affected by testicular cancer and their families.


3. Educate men and boys on risk factors and encourage them to seek treatment.


Our role as a global connector is what sets us apart. We have a stake in the ground and access to resources and researchers in 21 countries. This puts us in a unique position to raise and invest significant funds in the testicular cancer space.

Download our full funding strategy (English only PDF)


Programmes we're funding

In 2013 our Global Action Plan (GAP) expanded to cover testicular cancer. GAP is a global initiative run wholly by the Movember Foundation. We also fund country and community-specific testicular cancer programs in partnership with leading organisations in the field, where these programmes are likely to have a significant impact and can be scaled up to a national or international level.

An innovative global approach


Our Global Action Plan


Recent testicular cancer initiatives around the world


Testicular Cancer Research Breakthrough

We funded the largest comprehensive sequencing study of testicular tumours published to date. This has lead to several important discoveries that improve our understanding of testicular cancer and how to treat it effectively.


Supporting the European contribution to the TIGER trial

We've partnered with the European Organisation for Research and Treatment of Cancer to fund a multi-national clinical trial to determine which therapy works best for men who've been treated for testicular cancer, but in whom the cancer has returned.
We fund TIGER trial participation in Belgium, Denmark, Germany, the Netherlands, Spain and Switzerland.


View all testicular cancer programmes (English Only)



- Paul Villanti, Executive Director, Programmes